Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AYX1: Phase II started

    Adynxx Inc., San Francisco, Calif. Product: AYX1 Business: Neurology Molecular target: Early growth response 1 (EGR1) Description: Synthetic, dsDNA small molecule inhibitor of early growth response 1 (EGR1) Indication: …

    Published on 7/21/2014
  • CF102: Compassionate use program started

    Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Product: CF102 Business: Cancer Molecular target: Adenosine A3 receptor (ADORA3) Description: Nucleoside adenosine A3 receptor (ADORA3) agonist …

    Published on 7/21/2014
  • Clonidine: Completed Phase III enrollment

    Arcion Therapeutics Inc., Baltimore, Md. BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Product: Clonidine (clonidine topical gel) (formerly ARC-4558) Business: Neurology Molecular target: NA …

    Published on 7/21/2014
  • CTP-354: Phase I ongoing

    Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: CTP-354 (formerly C-21191) Business: Musculoskeletal Molecular target: GABA receptor Description: Deuterium-modified subtype-selective GABA A …

    Published on 7/21/2014
  • DEZ-001: Phase I start

    Dezima Pharma B.V., Naarden, the Netherlands Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: DEZ-001, TA-8995 Business: Endocrine/Metabolic Molecular target: Cholesteryl ester transfer protein (CETP) …

    Published on 7/21/2014
  • HaMPCs: Completed Phase IIb enrollment

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: HaMPCs, ReJoin Business: Autoimmune Molecular target: NA Description: Autologous human adipose tissue-derived mesenchymal precursor cells …

    Published on 7/21/2014
  • Inhaled nitric oxide: Completed Phase II enrollment

    Bellerophon Therapeutics LLC, Hampton, N.J. Product: Inhaled nitric oxide (NO) with the INOpulse DS drug-delivery system Business: Cardiovascular Molecular target: Not applicable Description: Combination product …

    Published on 7/21/2014
  • Nalbuphine ER: Phase II/III started

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (OPRM1) (MOR); Kappa …

    Published on 7/21/2014
  • Oxycodone/naltrexone: Pivotal trial started

    Elite Pharmaceuticals Inc. (OTCBB:ELTP), Northvale, N.J. Product: Oxycodone/naltrexone (ELI-201) Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Abuse-deterrent formulation of …

    Published on 7/21/2014
  • Palovarotene: Phase II started

    Clementia Pharmaceuticals Inc., Dorval, Quebec Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Palovarotene (R667) (formerly RG667, CLM-001) Business: Musculoskeletal Molecular target: Retinoic acid receptor …

    Published on 7/21/2014
  • ProCervix: Phase II ongoing

    Genticel S.A. (Euronext:GTCL), Labege, France Product: ProCervix Business: Cancer Molecular target: Human papillomavirus (HPV) antigens Description: Bivalent therapeutic cancer vaccine against HPV types 16 and 18 …

    Published on 7/21/2014
  • QPI-1007: Phase IIa started

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India BioSpring GmbH, Frankfurt, Germany Kunshan RiboQuark Pharmaceutical Technology Co. Ltd., Kunshan, China SBI Biotech Co. Ltd., Tokyo, Japan Product: QPI-1007 …

    Published on 7/21/2014
  • Reolysin: Completed Phase II enrollment

    Andrus Reo Ltd., Moscow, Russia Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta Product: Reolysin Business: Cancer Molecular target: Not applicable Description: Formulation of human reovirus type 3 …

    Published on 7/21/2014
  • Rhopressa: Phase III started

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Rhopressa (AR-13324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the …

    Published on 7/21/2014
  • Selinexor: Phase II started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 7/21/2014
  • TKM-Ebola: Phase I hold

    Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C. Product: TKM-Ebola (TKM-100201) (formerly Ebola SNALP) Business: Infectious Molecular target: NA Description: Combination of short interfering RNAs (…

    Published on 7/21/2014
  • TPI 287: Phase I started

    Cortice Biosciences Inc., New York, N.Y. Product: TPI 287 Business: Neurology Molecular target: Not available Description: Third-generation taxane Indication: Treat progressive supranuclear palsy (PSP) and corticobasal …

    Published on 7/21/2014
  • XEN-D0501: Phase IIa started

    Ario Pharma Ltd., Cambridge, U.K. Product: XEN-D0501 Business: Pulmonary Molecular target: Transient receptor potential vanilloid 1 (TRPV1) (VR1) Description: Transient receptor potential vanilloid 1 (TRPV1; VR1) …

    Published on 7/21/2014
  • Zeneo Methotrexate: Clinical trial started

    Crossject S.A. (Euronext:ALCJ), Chenove, France Product: Zeneo Methotrexate Business: Autoimmune Molecular target: NA Description: Methotrexate delivered using the companys Zeneo needle-free injection system Indication:…

    Published on 7/21/2014
  • ZS-9: Completed Phase III enrollment

    ZS Pharma Inc. (NASDAQ:ZSPH), Coppell, Texas Product: ZS-9 Business: Hematology Molecular target: NA Description: Inorganic crystal form of zirconium silicate designed to trap potassium ions over other ions throughout …

    Published on 7/21/2014
  • Allob: Phase I/IIa started

    Bone Therapeutics S.A., Gosselies, Belgium Product: Allob Business: Musculoskeletal Molecular target: NA Description: Allogeneic osteoblastic cell therapy Indication: Treat delayed-union fractures Endpoint: Percentage …

    Published on 7/14/2014
  • Ampion: Phase I/II started

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide …

    Published on 7/14/2014
  • BAL30072: Phase I started

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: BAL30072 Business: Infectious Molecular target: NA Description: Siderophore sulfactam antibiotic Indication: Treat Gram-negative bacterial infection …

    Published on 7/14/2014
  • Bardoxolone methyl: Phase II started

    Reata Pharmaceuticals Inc., Irving, Texas AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Bardoxolone methyl (formerly RTA 402) Business: Cardiovascular Molecular …

    Published on 7/14/2014
  • BeiGene-290: Phase I started

    BeiGene Co. Ltd., Beijing, China Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: BeiGene-290, BGB-290 Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Poly(ADP-ribose) polymerase (…

    Published on 7/14/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993